Nearly half of the biotech and technology start-ups seeking IPOs are opting for confidential filings, according to lawyer with Cooley
Companies choosing confidential filings often have concerns about sensitive information being released to the market in the early stages of the IPO process, which could attract scrutiny or allegations from competitors, Michael Yu, corporate partner at the firm, said in an interview.
“Some worry that, if they make a public filing, competitors or other parties will discover their listing timeline and could make complaints or take advantage of what is disclosed,” he said. “There is always a risk of allegations, intellectual property infringement or challenges to the accuracy of their data.”
Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with 88 TCF vendor(s) and 20 ad partner(s), or used specifically by this site or app.
Some vendors may process your personal data on the basis of legitimate interest, which you can object to by managing your options below. Look for a link at the bottom of this page or in the site menu to manage or withdraw consent in privacy and cookie settings.
